NCT00367692终止1 期
An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 12 人开始时间: 2006年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 12
- 主要终点
- To evaluate by IVCM the effect of a single dose of PSI-697 on leukocyte rolling in scleral blood vessels of subjects with scleritis.
研究概览
简要总结
To evaluate the safety of an orally administered single dose of PSI-697 in subjects with scleritis, as a model of inflammatory disease. To evaluate by in vivo confocal microscopy (IVCM) the effect of a single dose of PSI-697 on leukocyte rolling in the scleral blood vessels of subjects with scleritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion: Age 18 or higher; A negative urine pregnancy test at screening for female subjects; Female subjects must be postmenopausal or surgically sterile.
排除标准
- •Exclusion: Isolated episcleritis; Isolated posterior scleritis; Infectious scleritis.
结局指标
主要结局
To evaluate by IVCM the effect of a single dose of PSI-697 on leukocyte rolling in scleral blood vessels of subjects with scleritis.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01154348Shionogi34
已完成
1 期
Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral AnticoagulantCoagulation DisorderNCT06372483VarmX B.V.40
终止
2 期
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)Covid19NCT04900428Sorrento Therapeutics, Inc.179
已完成
1 期
First Time in Human Study With GSK1325756Pulmonary Disease, Chronic ObstructiveNCT01209052GlaxoSmithKline58
已完成
1 期
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal VolunteersMuscle LossNCT00755638Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA48